<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102141</url>
  </required_header>
  <id_info>
    <org_study_id>91202</org_study_id>
    <secondary_id>306743</secondary_id>
    <nct_id>NCT00102141</nct_id>
  </id_info>
  <brief_title>Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-estradiol 1 mg, Drospirenone 2 mg /17ß-estradiol 1 mg, Drospirenone 1 mg /17ß-estradiol 1 mg) Combinations and 17ß-estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8
      weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the
      relief of vasomotor symptoms and who have hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer
      HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in systolic office blood pressure measured at through</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in 24-hour systolic ambulatory blood pressure measurement (ABPM)</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in diastolic blood pressure measured at through</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in 24-hour diastolic ABPM</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in daytime systolic ABPM</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in daytime diastolic ABPM</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in nighttime systolic ABPM</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in nighttime diastolic ABPM</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in systolic APBM at through</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in diastolic APBM at through</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Hypertension</condition>
  <condition>Postmenopause</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)</intervention_name>
    <description>Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)</intervention_name>
    <description>Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)</intervention_name>
    <description>Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)</intervention_name>
    <description>1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, given as tablets orally once daily in the morning for 8 weeks</description>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Have hypertension- Are currently taking antihypertensive medications-
        Have had natural menopause at least 1 year prior to screening- Must require hormone therapy
        in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2005</study_first_submitted>
  <study_first_submitted_qc>January 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2005</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmenopausal</keyword>
  <keyword>vasomotor symptoms</keyword>
  <keyword>essential hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

